Early Rash Development May Signal Superior Benefit With Lapatinib

Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.

Lapatinib SpringerLink

Early Rash Development May Signal Superior Benefit With Lapatinib - Cancer Therapy Advisor

Frontiers Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study

Lapatinib: A competitor or companion to trastuzumab? - ScienceDirect

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

Forest plots showing heterogeneity by rash phenotype in the TþL

PDF) Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical

Prognostic value of early rash in all lapatinib-containing treatment arms*

Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+ Trastuzumab Therapy - Cancer Therapy Advisor